Maze Therapeutics (NASDAQ:MAZE) Upgraded at Mizuho

Mizuho upgraded shares of Maze Therapeutics (NASDAQ:MAZE) to a strong-buy rating in a research report sent to investors on Wednesday morning,Zacks.com reports.

Several other research firms also recently issued reports on MAZE. Lifesci Capital upgraded Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating on shares of Maze Therapeutics in a research report on Wednesday, January 28th. BTIG Research restated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Monday, March 9th. Finally, Raymond James Financial began coverage on shares of Maze Therapeutics in a research report on Thursday, November 13th. They issued an “outperform” rating and a $48.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Maze Therapeutics presently has an average rating of “Buy” and an average target price of $54.63.

Maze Therapeutics Stock Down 3.1%

Shares of Maze Therapeutics stock opened at $50.21 on Wednesday. Maze Therapeutics has a 12-month low of $6.71 and a 12-month high of $52.86. The firm has a market capitalization of $2.42 billion, a PE ratio of -2.40 and a beta of 4.47. The stock’s fifty day moving average is $44.82 and its 200-day moving average is $35.59.

Insider Buying and Selling

In other news, SVP Amy Bachrodt sold 5,000 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $46.04, for a total value of $230,200.00. Following the transaction, the senior vice president owned 12,965 shares in the company, valued at $596,908.60. This represents a 27.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction dated Thursday, January 29th. The shares were sold at an average price of $44.27, for a total value of $332,025.00. Following the completion of the transaction, the insider owned 10,503 shares in the company, valued at $464,967.81. This represents a 41.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 230,000 shares of company stock valued at $9,768,292.

Institutional Trading of Maze Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd purchased a new position in Maze Therapeutics during the fourth quarter valued at approximately $145,000. Invesco Ltd. lifted its position in Maze Therapeutics by 1.5% in the 4th quarter. Invesco Ltd. now owns 134,033 shares of the company’s stock worth $5,553,000 after buying an additional 1,971 shares in the last quarter. ADAR1 Capital Management LLC lifted its position in Maze Therapeutics by 589.3% in the 4th quarter. ADAR1 Capital Management LLC now owns 179,532 shares of the company’s stock worth $7,438,000 after buying an additional 153,487 shares in the last quarter. XTX Topco Ltd boosted its stake in shares of Maze Therapeutics by 22.9% during the 4th quarter. XTX Topco Ltd now owns 33,021 shares of the company’s stock valued at $1,368,000 after buying an additional 6,154 shares during the period. Finally, Wellington Management Group LLP acquired a new stake in shares of Maze Therapeutics during the 4th quarter valued at $2,536,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.